NFKBIA and neoplasm: Therefore, inhibition of NFκB by upregulating IκBα protein and subsequent creation of NFκB-IκBα complexes may be, at least in part, the mechanism behind proteasome inhibition and XPO1 inhibitor anti-tumor synergy.